Exscientia’s Oncology Joint Venture With GT Apeiron Therapeutics

Allen & Overy has advised Exscientia on the matter.

The collaboration will leverage Exscientia’s AI-driven drug discovery platform to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies.

Expanding on an existing CDK7 drug discovery partnership, the collaboration includes additional CDK targeting drugs. The potent, highly selective, non-covalent CDK7 compounds have demonstrated consistent tumour responses in xenograft models as well as exceptional pharmacokinetics. In addition, using live primary tissue samples from ovarian cancer patients, the CDK7 inhibitors showed both enhanced tumour cell cytotoxicity as well as selectivity over immune cells in the same microenvironment.

All pipeline products will be equally owned and Exscientia holds an equity stake in GTA.

Exscientia is an AI-driven pharmatech company committed to discovering and designing the best possible medicines in the fastest and most effective manner. 

GT Apeiron Therapeutics is strategically based in Shanghai and in the San Francisco Bay Area, with significant collaborations in the UK enabling us to tap into technologies and talent from all three continents.

The A&O team was led by London partner Jim Ford (Picture), assisted by London associate Megan McMellon.
 

Involved fees earner: Jim Ford – Allen & Overy; Megan McMellon – Allen & Overy;

Law Firms: Allen & Overy;

Clients: Exscientia;

Federica Tiefenthaler

Author: Federica Tiefenthaler